Hirokazu Okada

List of Publications by Year
in descending order

100	4,876	186265 28	91884 69
papers	citations	h-index	g-index

104	104	104	4734
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	COVID-19 and the kidney diseases (Adult). Japanese Journal of Pediatric Nephrology, 2022, 35, .	0.0	0
2	Framework for estimating renal function using magnetic resonance imaging. Journal of Medical Imaging, 2022, 9, 024501.	1.5	1
3	Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort Study. Journal of Nephrology, 2022, 35, 1135-1144.	2.0	3
4	The relationship between imaging features of diffusion-weighted imaging and prognosis of chronic kidney disease. Kidney International, 2022, 101, 1083.	5.2	1
5	MO316: Eculizumab for Adult Patients With Atypical Haemolytic-Uremic Syndrome: Full Dataset Analysis of Post-Marketing Surveillance in Japan. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
6	Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan. Clinical and Experimental Nephrology, 2022, 26, 974-981.	1.6	3
7	Predictors of early remission of proteinuria in adult patients with minimal change disease: a retrospective cohort study. Scientific Reports, 2022, 12, .	3.3	3
8	Recommendations by the Asian Pacific society of nephrology (<scp>APSN</scp>) on the appropriate use of <scp>HIFâ€PH</scp> inhibitors. Nephrology, 2021, 26, 105-118.	1.6	60
9	Efficacy of aerobic exercise on the cardiometabolic and renal outcomes in patients with chronic kidney disease: a systematic review of randomized controlled trials. Journal of Nephrology, 2021, 34, 155-164.	2.0	20
10	Kidney biopsy guidebook 2020 in Japan. Clinical and Experimental Nephrology, 2021, 25, 325-364.	1.6	18
11	Incidence and factors associated with prescribing reninâ€angiotensinâ€system inhibitors in adult idiopathic nephrotic syndrome: A nationwide cohort study. Journal of Clinical Hypertension, 2021, 23, 999-1007.	2.0	4
12	Comparison of annual eGFR decline among primary kidney diseases in patients with CKD G3b-5: results from a REACH-J CKD cohort study. Clinical and Experimental Nephrology, 2021, 25, 902-910.	1.6	5
13	Application of Magnetic Resonance Imaging in the Evaluation of Nutritional Status: A Literature Review with Focus on Dialysis Patients. Nutrients, 2021, 13, 2037.	4.1	5
14	Physical functioning in patients with chronic kidney disease stage G3bâ€5 in Japan: The reachâ€J CKD cohort study. Nephrology, 2021, 26, 981-987.	1.6	0
15	A digest from evidence-based Clinical Practice Guideline for Polycystic Kidney Disease 2020. Clinical and Experimental Nephrology, 2021, 25, 1292-1302.	1.6	8
16	Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database. Diabetes Care, 2021, 44, 2542-2551.	8.6	42
17	A digest of the evidence-based Clinical Practice Guideline for Rapidly Progressive Glomerulonephritis 2020. Clinical and Experimental Nephrology, 2021, 25, 1286-1291.	1.6	2
18	A digest from evidence-based clinical practice guideline for IgA nephropathy 2020. Clinical and Experimental Nephrology, 2021, 25, 1269-1276.	1.6	8

#	Article	IF	Citations
19	A digest of the Evidence-Based Clinical Practice Guideline for Nephrotic Syndrome 2020. Clinical and Experimental Nephrology, 2021, 25, 1277-1285.	1.6	21
20	Comparison of multiparametric magnetic resonance imaging sequences with laboratory parameters for prognosticating renal function in chronic kidney disease. Scientific Reports, 2021, 11, 22129.	3.3	6
21	Reduced oxygenation but not fibrosis defined by functional magnetic resonance imaging predicts the long-term progression of chronic kidney disease. Nephrology Dialysis Transplantation, 2020, 35, 964-970.	0.7	40
22	Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS ONE, 2020, 15, e0236132.	2.5	46
23	ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE. Nephrology, 2020, 25, 12-45.	1.6	17
24	ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE â€“ EXECUTIVE SUMMARY. Nephrology, 2020, 25, 3-11.	1.6	9
25	Asian Pacific Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease â€“ An Executive Summary. Nephrology, 2020, 25, 809-817.	1.6	12
26	P0822ESTIMATED GFR DECLINE OF PKD PATIENTS IN CKD G3B-5 WAS AS FAST AS THAT OF DKD PATIENTS: A RESULT FROM A JAPANESE COHORT STUDY FOR PATIENTS WITH ADVANCED CKD, THE REACH-J STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
27	Tocilizumab-induced immunocomplex glomerulonephritis: a report of two cases. CEN Case Reports, 2020, 9, 318-325.	0.9	2
28	A nationwide survey on clinical practice patterns and bleeding complications of percutaneous native kidney biopsy in Japan. Clinical and Experimental Nephrology, 2020, 24, 389-401.	1.6	13
29	Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS). Clinical and Experimental Nephrology, 2020, 24, 526-540.	1.6	33
30	Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS). Clinical and Experimental Nephrology, 2020, 24, 893-909.	1.6	6
31	J-CKD-DB: a nationwide multicentre electronic health record-based chronic kidney disease database in Japan. Scientific Reports, 2020, 10, 7351.	3.3	37
32	Prevalences of hyperuricemia and electrolyte abnormalities in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS ONE, 2020, 15, e0240402.	2.5	17
33	2. Strategic Application of Clinical Practice Guideline for CKD Management. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 1698-1707.	0.0	0
34	Safety and effectiveness of eculizumab for pediatric patients with atypical hemolyticâ€“uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clinical and Experimental Nephrology, 2019, 23, 112-121.	1.6	31
35	Safety and effectiveness of eculizumab for adult patients with atypical hemolyticâ€“uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clinical and Experimental Nephrology, 2019, 23, 65-75.	1.6	15
36	Variations in actual practice patterns and their deviations from the clinical practice guidelines for nephrotic syndrome in Japan: certified nephrologistsâ€™ questionnaire survey. Clinical and Experimental Nephrology, 2019, 23, 1288-1297.	1.6	7

#	Article	IF	Citations
37	Cellular communication network factor 2 (CCN2) promotes the progression of acute kidney injury to chronic kidney disease. Biochemical and Biophysical Research Communications, 2019, 517, 96-102.	2.1	6
38	Glomerular solidification is associated with nephritis-related clinical parameters in IgA nephropathy. Renal Failure, 2019, 41, 893-898.	2.1	0
39	Predictors of long-term prognosis in acute kidney injury survivors who require continuous renal replacement therapy after cardiovascular surgery. PLoS ONE, 2019, 14, e0211429.	2.5	5
40	Regional prescription surveillance of phosphate binders in the western Saitama area: the substantial role of ferric citrate hydrate in improving serum phosphorus levels and erythropoiesis. Clinical and Experimental Nephrology, 2019, 23, 841-851.	1.6	2
41	I. Definition of Diabetic Kidney Disease and Criteria for Consultation with a Nephrology Specialist. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 901-906.	0.0	0
42	Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study. Clinical and Experimental Nephrology, 2018, 22, 1266-1280.	1.6	21
43	Essentials from clinical practice guidelines for CKD stage G3b-5 2017. Clinical and Experimental Nephrology, 2018, 22, 245-248.	1.6	6
44	Controversies of the classification of TMA and the terminology of aHUS. Clinical and Experimental Nephrology, 2018, 22, 979-980.	1.6	10
45	Clinico-pathological features of kidney disease in diabetic cases. Clinical and Experimental Nephrology, 2018, 22, 1046-1051.	1.6	20
46	The Japanese clinical practice guideline for acute kidney injury 2016. Clinical and Experimental Nephrology, 2018, 22, 985-1045.	1.6	40
47	Guidelines for clinical evaluation of chronic kidney disease. Clinical and Experimental Nephrology, 2018, 22, 1446-1475.	1.6	23
48	The Japanese Clinical Practice Guideline for acute kidney injury 2016. Journal of Intensive Care, 2018, 6, 48.	2.9	35
49	A consensus statement on health-care transition of patients with childhood-onset chronic kidney diseases: providing adequate medical care in adolescence and young adulthood. Clinical and Experimental Nephrology, 2018, 22, 743-751.	1.6	12
50	A nationwide prospective cohort study of patients with advanced chronic kidney disease in Japan: The Reach-J CKD cohort study. Clinical and Experimental Nephrology, 2018, 22, 309-317.	1.6	8
51	Title is missing!. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 70-74.	0.0	0
52	Successful Treatment of C1q Nephropathy by Lowâ€Ðensity Lipoprotein Apheresis. Therapeutic Apheresis and Dialysis, 2016, 20, 530-531.	0.9	2
53	Clinical guides for atypical hemolytic uremic syndrome in Japan. Pediatrics International, 2016, 58, 549-555.	0.5	19
54	Clinical guides for atypical hemolytic uremic syndrome in Japan. Clinical and Experimental Nephrology, 2016, 20, 536-543.	1.6	41

#	Article	IF	Citations
55	Transition of adolescent and young adult patients with childhood-onset chronic kidney disease from pediatric to adult renal services: a nationwide survey in Japan. Clinical and Experimental Nephrology, 2016, 20, 918-925.	1.6	16
56	Kidney Diseases and Fibrogenesis. The Journal of the Japanese Society of Internal Medicine, 2015, 104, 1658-1664.	0.0	1
57	Decline of Renal Function and Progression of Left Ventricular Hypertrophy Are Independently Determined in Chronic Kidney Disease Stages 3-5. Pulse, 2015, 2, 29-37.	1.9	0
58	Successful Prednisolone Therapy in Elderly Patients with Severe Forms of Henochâ€“SchÃ¶nlein Purpura Nephritis. Japanese Clinical Medicine, 2015, 6, JCM.S23093.	1.9	5
59	Patients with biopsy-proven nephrosclerosis and moderately impaired renal function have a higher risk for cardiovascular disease: 15 yearsâ€™ experience in a single, kidney disease center. Therapeutic Advances in Cardiovascular Disease, 2015, 9, 77-86.	2.1	5
60	Effects of cell-type-specific expression of a pan-caspase inhibitor on renal fibrogenesis. Clinical and Experimental Nephrology, 2015, 19, 350-358.	1.6	3
61	The contribution of epithelial-mesenchymal transition to renal fibrosis differs among kidney disease models. Kidney International, 2015, 87, 233-238.	5.2	84
62	Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the joint committee of the Japanese society of nephrology and the Japan pediatric society. Clinical and Experimental Nephrology, 2014, 18, 4-9.	1.6	24
63	Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the <scp>J</scp>oint <scp>C</scp>ommittee of the <scp>J</scp>apanese <scp>S</scp>ociety of <scp>N</scp>ephrology and the <scp>J</scp>apan <scp>P</scp>ediatric <scp>S</scp>ociety. Pediatrics International, 2014, 56, 1-5.	0.5	29
64	Role of Pulse Wave Velocity in Patients with Chronic Kidney Disease Stages 3-5 on Long-Term Follow-Up. Pulse, 2014, 2, 1-10.	1.9	5
65	Combination of Echocardiography and Pulse Wave Velocity Provides Clues for the Differentiation between White Coat Hypertension and Hypertension in Postmenopausal Women. Pulse, 2013, 1, 131-138.	1.9	4
66	Gastric and colonic ulcers induced by a nonsteroidal anti-inflammatory drug. Progress of Digestive Endoscopy, 2013, 83, 116-117.	0.0	0
67	A case of constrictive ischemic colitis in the right side of the transverse colon. Progress of Digestive Endoscopy, 2013, 82, 190-191.	0.0	0
68	Targeted expression of a pan-caspase inhibitor in tubular epithelium attenuates interstitial inflammation and fibrogenesis in nephritic but not nephrotic mice. Kidney International, 2012, 82, 980-989.	5.2	7
69	Dopamine D1-Like Receptor Antagonist Attenuates Th17-Mediated Immune Response and Ovalbumin Antigen-Induced Neutrophilic Airway Inflammation. Journal of Immunology, 2011, 186, 5975-5982.	0.8	74
70	Noninvasive Evaluation of Kidney Hypoxia and Fibrosis Using Magnetic Resonance Imaging. Journal of the American Society of Nephrology: JASN, 2011, 22, 1429-1434.	6.1	298
71	Fibroblast Expression of an IÎºB Dominant-Negative Transgene Attenuates Renal Fibrosis. Journal of the American Society of Nephrology: JASN, 2010, 21, 2047-2052.	6.1	44
72	Decreased klotho expression in early aldosteroneâ€induced hypertension. FASEB Journal, 2010, 24, lb698.	0.5	0

#	Article	IF	Citations
73	D1-Like Receptor Antagonist Inhibits IL-17 Expression and Attenuates Crescent Formation in Nephrotoxic Serum Nephritis. American Journal of Nephrology, 2009, 30, 274-279.	3.1	22
74	Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney diseases. CKJ: Clinical Kidney Journal, 2009, 2, 192-193.	2.9	9
75	A case report suggesting the occurrence of epithelialâ€“mesenchymal transition in obstructive nephropathy. Clinical and Experimental Nephrology, 2009, 13, 385-388.	1.6	14
76	Viruses may trigger allopurinol hypersensitivity syndrome. CKJ: Clinical Kidney Journal, 2008, 1, 273-274.	2.9	2
77	Poly(ADP-Ribose) Polymerase-1 Enhances Transcription of the Profibrotic CCN2 Gene. Journal of the American Society of Nephrology: JASN, 2008, 19, 933-942.	6.1	27
78	Dexamethasone Induces Connective Tissue Growth Factor Expression in Renal Tubular Epithelial Cells in a Mouse Strain-Specific Manner. American Journal of Pathology, 2006, 168, 737-747.	3.8	42
79	A Possible Anti-Inflammatory Role of Angiotensin II Type 2 Receptor in Immune-Mediated Glomerulonephritis during Type 1 Receptor Blockade. American Journal of Pathology, 2006, 169, 1577-1589.	3.8	41
80	Decline of Renal Function Is Associated with Proteinuria and Systolic Blood Pressure in the Morning in Diabetic Nephropathy. Clinical and Experimental Hypertension, 2005, 27, 129-138.	1.3	14
81	Connective Tissue Growth Factor Expressed in Tubular Epithelium Plays a Pivotal Role in Renal Fibrogenesis. Journal of the American Society of Nephrology: JASN, 2005, 16, 133-143.	6.1	170
82	Angiotensin II type 1 receptor blockade attenuates renal fibrogenesis in an immune-mediated nephritic kidney through counter-activation of angiotensin II type 2 receptor. Biochemical and Biophysical Research Communications, 2004, 314, 403-408.	2.1	20
83	Selective depletion of fibroblasts preserves morphology and the functional integrity of peritoneum in transgenic mice with peritoneal fibrosing syndrome. Kidney International, 2003, 64, 1722-1732.	5.2	38
84	Hepatocyte growth factor counteracts transforming growth factorâ€Î²1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice. FASEB Journal, 2003, 17, 268-270.	0.5	128
85	TGF-Î²1 and HGF coordinately facilitate collagen turnover in subepithelial mesenchyme. Biochemical and Biophysical Research Communications, 2002, 297, 255-260.	2.1	18
86	Evidence that fibroblasts derive from epithelium during tissue fibrosis. Journal of Clinical Investigation, 2002, 110, 341-350.	8.2	1,447
87	Evidence that fibroblasts derive from epithelium during tissue fibrosis. Journal of Clinical Investigation, 2002, 110, 341-350.	8.2	1,098
88	New Animal Models for Encapsulating Peritoneal Sclerosisâ€”Role of Acidic Solution. Peritoneal Dialysis International, 2001, 21, 349-353.	2.3	36
89	Improved Outcome Prediction for Patients with Multiple Organ Failure Undergoing Continuous Hemodiafiltration. Therapeutic Apheresis and Dialysis, 2001, 5, 31-35.	0.9	4
90	Conditional Abatement of Tissue Fibrosis Using Nucleoside Analogs to Selectively Corrupt DNA Replication in Transgenic Fibroblasts. Molecular Therapy, 2001, 3, 149-159.	8.2	99

#	Article	IF	Citations
91	Progressive renal fibrosis in murine polycystic kidney disease: An immunohistochemical observation. Kidney International, 2000, 58, 587-597.	5.2	143
92	Inhibition of monocyte chemoattractant protein-1 expression in tubular epithelium attenuates tubulointerstitial alteration in rat Goodpasture syndrome. Kidney International, 2000, 57, 927-936.	5.2	34
93	INFLUENCE OF THE TIMING OF INITIATING ANTIHYPERTENSIVE THERAPY IN HYPERTENSIVE RATS WITH RENAL FAILURE. Clinical and Experimental Hypertension, 2000, 22, 521-529.	1.3	1
94	Nifedipine and Arotinolol in Combination for Accelerated-Malignant Hypertension: Results of One Year Follow-Up.. Hypertension Research, 1999, 22, 75-80.	2.7	8
95	Comparative Study of Efficacy of Plasma Exchange Versus Intravenous Gammaglobulin Treatment on Acute Postinfectious Polyradiculoneuropathy: A Preliminary Report. Therapeutic Apheresis and Dialysis, 1998, 2, 288-291.	0.6	15
96	Biophysical Signals Underlying Myogenic Responses in Rat Interlobular Artery. Hypertension, 1998, 32, 1060-1065.	2.7	22
97	Does Combined Therapy of Ca-channel Blocker and Angiotensin Converting Enzyme Inhibitor Exceed Monotherapy in Renal Protection Against Hypertensive Injury in Rats?. Clinical and Experimental Hypertension, 1996, 18, 243-256.	1.3	6
98	Possible Mechanisms of Renal Fibrosis. Contributions To Nephrology, 1996, 118, 147-154.	1.1	42
99	The Effects of Chronic, and Selective Vasopressin Receptor Blockade in Spontaneously Hypertensive Rats. International Heart Journal, 1995, 36, 538-538.	0.6	0
100	Effects of Vasopressin V1 and V2 Receptor Antagonists on Progressive Renal Failure in Rats. Clinical Science, 1994, 86, 399-404.	4.3	29